Management of Dry Eye Toxicity After Treatment With 177Lu-PSMA-617 Radioligand Therapy.

MLA

Pepin, Abigail, et al. “Management of Dry Eye Toxicity After Treatment With 177Lu-PSMA-617 Radioligand Therapy.” Practical Radiation Oncology, vol. 14, no. 4, July 2024, pp. 301–04. EBSCOhost, https://doi.org/10.1016/j.prro.2024.04.001.

APA

Pepin, A., Lee, V., O’Brien, S., Mulugeta, P., & Taunk, N. K. (2024). Management of Dry Eye Toxicity After Treatment With 177Lu-PSMA-617 Radioligand Therapy. Practical Radiation Oncology, 14(4), 301–304. https://doi.org/10.1016/j.prro.2024.04.001

Chicago

Pepin, Abigail, Vivian Lee, Sophia O’Brien, Philipose Mulugeta, and Neil K. Taunk. 2024. “Management of Dry Eye Toxicity After Treatment With 177Lu-PSMA-617 Radioligand Therapy.” Practical Radiation Oncology 14 (4): 301–4. doi:10.1016/j.prro.2024.04.001.